Tempus Shares Jump on FDA's Special Clearance for Tempus Pixel
By Dean Seal
Shares of Tempus AI climbed after federal regulators gave special clearance to the company's AI-powered cardiac imaging platform, Tempus Pixel.
The stock was up 12% at $87.64 in early trading. Shares have more than doubled since the start of the year and are nearing a 52-week high.
The healthcare-technology company said Thursday morning that the U.S. Food and Drug Administration has granted 510(k) clearance for its updated Tempus Pixel, which has enhanced capabilities for cardiac magnetic resonance image analysis.
The FDA's clearance allows the Tempus Pixel to be marketed in the U.S.
"This marks another important regulatory milestone for Tempus and underscores our commitment to advancing AI-driven imaging technology that is both scientifically rigorous and clinically meaningful," Chris Scotto DiVetta, senior vice president of AI applications, said in a statement.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 11, 2025 11:55 ET (15:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States